Key result
Colchicine's unexpectedly neutral effect in patients with recent myocardial infarction may be explained by concurrent clopidogrel use, which blunts its clinical effect by reducing neutrophil count.
Why the study?
Does concurrent use of clopidogrel blunt the anti-inflammatory benefits of colchicine in patients with acute coronary syndrome?
Does concurrent use of clopidogrel blunt the anti-inflammatory benefits of colchicine in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
This paper proposes the hypothesis that the neutral effect of colchicine in recent MI trials may be due to a competitive effect of clopidogrel on neutrophil counts.
Neutrophil count is a risk factor for myocardial infarction (MI). Colchicine, a drug known as an anti-inflammatory, acts by selectively concentrating on neutrophils and impairing their function. Colchicine has been used successfully in the prevention of vascular events in patients with coronary artery disease (CAD), but recently the largest clinical trial carried out with colchicine in this clinical setting was unexpectedly neutral in the comparison of placebo and colchicine in patients with recent MI. Among the characteristics that distinguish patients with acute coronary syndromes (ACS) from established CAD is the dual antiplatelet therapy (DAPT), often consisting of aspirin and clopidogrel. Clopidogrel significantly reduces neutrophil count and could play a competitive role with colchicine by blunting its clinical effect.
No takes yet. Share an insight, caveat, or question.
Servi et al. (2025) conducted an editorial in Acute coronary syndrome. Colchicine vs. Placebo was evaluated. Colchicine's unexpectedly neutral effect in patients with recent myocardial infarction may be explained by concurrent clopidogrel use, which blunts its clinical effect by reducing neutrophil count.
Synapse has enriched 10 related papers. Consider them for comparative context: